You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
24 April 2024
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
18 April 2024
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
16 April 2024
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4 April 2024
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK